CBC-derived leukocyte differential indices in relation to insulin resistance in women with polycystic ovary syndrome: a cross-sectional study

NATALIA PIÓRKOWSKA[1*], ANNA BIZOŃ[2], KACPER BIZOŃ[3], GRZEGORZ FRANIK[4], KAROLINA JONCZYK

[1]*Department of Applied Computer Science, Faculty of Computer Science and Telecommunications, Wroclaw University of Science and Technology, Wrocław, Poland*
[2]*Department of Toxicology, Faculty of Pharmacy, Wroclaw Medical University, Wrocław, Poland*
[3]*Student of AuPolycystic ovary syndrometomation and Robotics, Faculty of Electronics, Photonics and Microsystems, Wrocław University of Science and Technology, Wrocław, Poland*
[4]*Department of Endocrinological Gynecology, Medical University of Silesia, 40-752 Katowice, Poland*

*

ABSTRACT

Context
Polycystic ovary syndrome (PCOS) is often accompanied by reduced insulin sensitivity and low-grade inflammation, which may increase long-term cardiometabolic risk. Complete blood count (CBC)–derived leukocyte indices are inexpensive, widely available markers that may reflect inflammatory status, but their links to metabolic features in PCOS are not well defined.

Objective
To evaluate associations between CBC-derived leukocyte differential indices, including derived ratios, and insulin resistance–related metabolic measures in women with PCOS.

Design
Cross-sectional observational study (2018–2025).

Settings
Single-center gynecological endocrinology clinic in Katowice, Poland.

Patients
Women with PCOS; 1315 individuals aged 16–25 years (median 21 years; IQR 19–22). Outcome-specific analytic samples varied by data availability.

Intervention
None

Main Outcome Measures
Primary outcomes were neutrophil percentage, lymphocyte percentage, and neutrophil-to-lymphocyte ratio (NLR). Secondary outcomes included additional leukocyte-related CBC parameters. Associations with insulin resistance–related metabolic measures were assessed using correlation and multivariable regression models.

---

*Corresponding author, e-mail: natalia.piorkowska@pwr.edu.pl

INTRODUCTION

PCOS is one of the most common endocrine disorders affecting women of reproductive age and represents a leading cause of anovulatory infertility (1). Four phenotypes of PCOS are commonly distinguished: phenotype A includes all three Rotterdam criterias, namely clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology (PCOM) on ultrasound. Phenotype B is diagnosed when hyperandrogenism coexists with ovulatory dysfunction. Phenotype C is characterized by hyperandrogenism and PCOM despite the presence of regular ovulatory cycles. Finally, Phenotype D presents with ovulatory or menstrual disturbances and PCOM in the absence of hyperandrogenism (2) (3). Despite unified diagnostic criteria, PCOS is clinically heterogeneous and encompasses distinct phenotypes characterized by varying combinations of ovulatory dysfunction, clinical and/or biochemical hyperandrogenism, and PCOM. This phenotypic diversity reflects differences not only in reproductive endocrine regulation but also in metabolic risk profiles and long-term cardiometabolic burden(4). Among these features, androgen excess plays a central role in PCOS pathophysiology and has been linked to disturbances in folliculogenesis, altered gonadotropin secretion, and adverse metabolic outcomes (5). Beyond its reproductive manifestations, PCOS is increasingly recognized as a systemic disorder frequently accompanied by insulin resistance, overweight or obesity, dyslipidemia, and elevated cardiovascular risk (6) (7) (8). These metabolic abnormalities are closely intertwined with chronic, low-grade inflammatory processes arising from the interplay between adipose tissue dysfunction, immune activation, and endocrine–metabolic signaling. Insulin resistance, in particular, represents a key pathophysiological link between metabolic dysfunction and inflammation in PCOS and may contribute to altered leukocyte profiles through its effects on innate and adaptive immune responses (9). CBC–derived leukocyte indices have emerged as practical and widely available markers of systemic inflammatory status. Leukocyte differential parameters, including neutrophil and lymphocyte proportions, as well as derived ratios such as NLR, have been associated with cardiometabolic risk, insulin resistance, and adverse outcomes in diverse clinical populations. These indices may reflect shifts toward innate immune activation and relative lymphocyte suppression, patterns that are biologically plausible in insulin-resistant and pro-inflammatory states. In women with PCOS, prior studies evaluating CBC-derived inflammatory markers have yielded inconsistent results (10). Some investigations have reported elevated NLR or altered leukocyte distributions, whereas others have found no significant differences or observed associations that were attenuated after adjustment for metabolic factors(11). Interpretation of the existing literature is limited by small sample sizes, heterogeneous phenotyping, and variable consideration of insulin resistance as a central confounder or mediator (8) (1). Moreover, many studies have focused on single hematological indices rather than examining leukocyte differential parameters within a broader metabolic context. Against this background, a clinically relevant gap remains regarding the extent to which routinely measured CBC-derived leukocyte indices are associated with insulin resistance–related metabolic features in women with PCOS. Addressing this gap is of particular importance because CBC is inexpensive, routinely obtained, and broadly accessible in clinical practice. Therefore, the aim of this cross-sectional study was to evaluate associations between CBC-derived leukocyte differential indices, including neutrophil percentage, lymphocyte percentage, and NLR, and insulin resistance in a large cohort of women with PCOS. Secondary analyses examined additional leukocyte-related CBC parameters and assessed the robustness of observed associations using complementary statistical approaches.

MATERIALS AND METHODS

Study Design and Population
This cross-sectional observational study was conducted in women diagnosed with PCOS who attended a single-center gynecological endocrinology clinic in Katowice, Poland, between 2018

and 2025. PCOS was diagnosed according to the Rotterdam criteria, requiring the presence of at least two of the following features: oligo- or anovulation, clinical and/or biochemical hyperandrogenism, and PCOM on ultrasound, after exclusion of related endocrine disorders. The analytic cohort comprised 1,315 women aged 16–25 years. The relatively narrow age range was chosen to limit confounding by age-related metabolic changes. For participants younger than 18 years, written informed consent was obtained from a parent or legal guardian in accordance with local regulations. All participants provided written informed consent prior to inclusion in the study. Outcome-specific analytic sample sizes varied depending on data availability for individual laboratory and metabolic variables.

Clinical and Laboratory Measurements

Venous blood samples were collected in the morning after an overnight fast as part of routine clinical evaluation. CBC parameters were measured using automated hematology analyzers according to standardized laboratory protocols. Leukocyte differential indices included neutrophil percentage, lymphocyte percentage, and additional leukocyte-related parameters evaluated in secondary analyses. NLR was calculated as the ratio of absolute neutrophil count to absolute lymphocyte count. Insulin resistance was assessed using the homeostasis model assessment of insulin resistance (HOMA-IR), calculated from fasting glucose and fasting insulin concentrations according to the standard formula. Due to right-skewed distribution, HOMA-IR values were log-transformed for selected analyses. Platelet-related indices and C-reactive protein were available only for a subset of participants and were therefore considered exploratory. Anthropometric measures, including body mass index (BMI), were not consistently available in the clinical records and were therefore not included in the present analyses.

Data Preprocessing and Handling of Missing Data

Data preprocessing and quality control were performed prior to statistical analysis. Continuous variables were inspected for distributional properties, and extreme outliers were evaluated using graphical and influence diagnostics. Variables with highly skewed distributions, including HOMA-IR, were log-transformed as appropriate. Missing data were assessed for each variable. Primary analyses were conducted using available-case data. To evaluate the robustness of findings, sensitivity analyses were performed in a complete-case dataset restricted to participants with non-missing values for leukocyte indices, insulin resistance measures, and covariates. No imputation procedures were applied.

Statistical Analysis

Descriptive statistics are reported as median and interquartile range (IQR) for continuous variables and as counts with percentages for categorical variables. Distributions of CBC-derived indices were visually inspected to guide the choice of statistical tests. Associations between insulin resistance measures and leukocyte-derived outcomes were first evaluated using correlation analyses. Both Pearson and Spearman correlation coefficients were calculated. To account for multiple testing, p-values were adjusted using the false discovery rate (FDR) method. Multivariable linear regression models were subsequently fitted to assess independent associations between insulin resistance and primary leukocyte outcomes, including neutrophil percentage, lymphocyte percentage, and NLR. Models were adjusted for age. Heteroskedasticity-consistent (HC3) standard errors were used to provide robust inference. Model diagnostics included assessment of residual distributions, leverage, and Cook's distance to identify potentially influential observations. Secondary analyses examined associations between insulin resistance and additional leukocyte-related CBC parameters. Results of secondary analyses were interpreted cautiously due to multiple testing and variable data availability. All statistical analyses were performed using Python (version 3.12.12). Statistical significance was defined as a two-sided adjusted p-value < 0.05.

Ethical Approval

The study protocol was approved by the appropriate institutional ethics committee in Poland (approval number: 254/2021). The study was conducted in accordance with the Declaration of Helsinki and applicable national regulations. Written informed consent was obtained from all participants, with parental or guardian consent obtained for participants younger than 18 years.

RESULTS

Study population and data availability

The analytic dataset comprised 1,315 women with PCOS aged 16–25 years (median age 21 years, interquartile range [IQR] 19–22). CBC–derived variables, insulin resistance measures, and covariates were extracted and standardized as described in the Methods. Outcome-specific analytic sample sizes varied according to data availability. Leukocyte differential indices and NLR were available for the majority of participants, whereas platelet-related indices and C-reactive protein showed substantial missingness and were therefore evaluated only in exploratory or secondary analyses.

Descriptive characteristics of CBC-derived leukocyte indices

Descriptive statistics for CBC-derived leukocyte parameters are summarized in Supplementary Table S1. Neutrophil and lymphocyte percentages showed distributions consistent with young reproductive-age populations, with moderate interindividual variability. The NLR demonstrated a right-skewed distribution, supporting the use of nonparametric correlation analyses as the primary analytical approach.

Associations between insulin resistance and primary leukocyte outcomes

Correlation analyses

In correlation analyses using the available-case dataset, insulin resistance was positively associated with markers of innate immune predominance. Higher HOMA-IR and log-transformed HOMA-IR values were associated with higher neutrophil percentages and higher NLR, and inversely associated with lymphocyte percentage. These associations were observed using both Pearson and Spearman correlation coefficients and remained statistically significant after correction for multiple testing using the false discovery rate (FDR) method.

Sensitivity analyses (complete-case)

To assess the stability of findings, correlations were re-evaluated in a complete-case dataset restricted to participants with non-missing values for leukocyte indices, insulin resistance measures, and covariates. The direction and magnitude of associations between insulin resistance and neutrophil percentage, lymphocyte percentage, and NLR were largely preserved, indicating that the results were not driven by patterns of missing data.

Multivariable regression analyses

Multivariable linear regression models with heteroskedasticity-consistent (HC3) standard errors were fitted to evaluate associations between insulin resistance and leukocyte-derived outcomes while accounting for age. In these models, higher insulin resistance remained independently associated with higher NLR and higher neutrophil percentage, as well as with lower lymphocyte percentage. Model diagnostics did not indicate undue influence of individual observations, and Cook's distance analyses identified no patterns suggestive of leverage-driven associations.

Secondary analyses of additional CBC-derived parameters

Secondary analyses examined associations between insulin resistance and other leukocyte-related CBC parameters, including monocyte, eosinophil, immature granulocyte percentages, and total white blood cell count. Associations with insulin resistance were weaker and less consistent than those observed for neutrophil percentage, lymphocyte percentage, and NLR, and several did not remain significant after correction for multiple comparisons.

Platelet-related indices and inflammatory markers
Analyses of platelet-related indices and C-reactive protein were limited by substantial missingness. As a result, no stable or generalizable associations between insulin resistance and platelet-related parameters could be established in this cohort. These findings are interpreted as exploratory and are not emphasized in the primary conclusions.

Summary of key findings
Collectively, these results demonstrate that insulin resistance in women with PCOS is associated with a shift in leukocyte differential profiles toward increased neutrophil predominance and reduced lymphocyte proportion, reflected by higher NLR values. These associations were consistent across correlation and regression analyses, robust to multiple-testing correction, and stable in sensitivity analyses accounting for missing data.

DISCUSSION

In this large cross-sectional cohort of young women with PCOS, we demonstrate that insulin resistance is consistently associated with alterations in CBC-derived leukocyte differential indices, characterized by higher neutrophil percentage, lower lymphocyte percentage, and elevated NLR. These associations were robust across correlation and multivariable regression analyses, persisted after correction for multiple testing, and remained stable in sensitivity analyses accounting for missing data. Together, these findings support the concept that insulin resistance is linked to a shift toward innate immune predominance in PCOS, even in a relatively young population.

Leukocyte differential indices as markers of metabolic–inflammatory dysregulation in PCOS
Neutrophil predominance and relative lymphocyte reduction, reflected by higher NLR, are well-established indicators of systemic inflammatory activation and have been associated with cardiometabolic risk in the general population. Our results extend these observations to women with PCOS by demonstrating that insulin resistance is associated not only with NLR but also with its underlying leukocyte components. This finding suggests that NLR captures biologically meaningful shifts in leukocyte composition rather than representing a purely statistical composite. The observed associations are biologically plausible. Insulin resistance is known to promote low-grade inflammation through multiple mechanisms, including activation of innate immune pathways, altered cytokine signaling, and changes in leukocyte trafficking. Neutrophils, as key effector cells of innate immunity, may be preferentially mobilized in insulin-resistant states, while relative lymphocyte suppression may reflect impaired adaptive immune regulation. Our findings are consistent with this framework and support the use of leukocyte differential indices as accessible markers of metabolic–inflammatory interactions in PCOS.

Comparison with previous studies
Prior studies examining CBC-derived inflammatory markers in PCOS have reported heterogeneous results, particularly with respect to NLR and platelet-related indices. Several investigations have described elevated NLR in PCOS compared with controls or positive associations with metabolic parameters, whereas others have reported null findings after adjustment for body

mass index or insulin resistance. Differences in study design, sample size, age distribution, and analytical strategies likely contribute to these inconsistencies. Our study addresses several limitations of the existing literature. The relatively large sample size, focus on a narrow age range, and explicit consideration of insulin resistance as a central exposure strengthen the interpretability of the findings. Moreover, by examining neutrophil and lymphocyte percentages alongside NLR, we provide additional insight into the cellular basis of previously reported associations.

Limited evidence for platelet-related indices in the present cohort Although platelet-related parameters and other CBC-derived indices have been proposed as inflammatory or prothrombotic markers in PCOS, our analyses were substantially limited by data availability. Platelet indices and C-reactive protein were missing for a large proportion of participants, precluding robust evaluation of their associations with insulin resistance. As a result, we were unable to confirm or refute prior reports linking platelet activation markers to PCOS-related metabolic risk. This limitation underscores the importance of carefully assessing data completeness when interpreting CBC-derived markers and highlights that routinely measured parameters may vary considerably in availability across clinical settings and time periods. Future studies with systematic platelet phenotyping and standardized inflammatory assessments will be required to clarify the role of platelet-related indices in PCOS.

Clinical and research implications

The present findings have several potential implications. From a clinical perspective, leukocyte differential indices and NLR are inexpensive, routinely available, and easily interpretable markers that may provide additional information about metabolic–inflammatory status in women with PCOS. While these markers are not diagnostic of insulin resistance, they may help identify individuals with a more pronounced inflammatory profile who could benefit from targeted metabolic evaluation or early lifestyle interventions. From a research standpoint, our results support the integration of simple hematological markers into studies of PCOS pathophysiology and cardiometabolic risk. Longitudinal studies are needed to determine whether leukocyte differential alterations precede the development of insulin resistance or reflect its downstream consequences. In addition, future work should explore whether these markers are modified by therapeutic interventions, such as weight loss, insulin-sensitizing agents, or anti-inflammatory strategies.

Strengths and limitations

Key strengths of this study include the large, well-characterized cohort, the focus on a young population with PCOS, and the use of complementary statistical approaches, including nonparametric correlations, multivariable regression with robust standard errors, and sensitivity analyses addressing missing data. These features enhance confidence in the robustness of the observed associations. The cross-sectional design precludes causal inference, and residual confounding by unmeasured factors such as adiposity distribution, physical activity, or dietary patterns cannot be excluded. Additionally, incomplete availability of platelet-related indices and inflammatory biomarkers limited the scope of secondary analyses. Finally, the study was conducted at a single center, which may affect generalizability to other populations or age groups. Several limitations should be acknowledged. First, anthropometric measures, including body mass index (BMI), were not available for a substantial proportion of participants and could not be included as covariates in the analyses. Given the close relationship between adiposity, insulin resistance, and systemic inflammation, residual confounding by unmeasured adiposity cannot be excluded. However, the observed associations between insulin resistance and leukocyte differential indices were consistent across analytical approaches and were detected in a relatively young and metabolically homogeneous population, partially mitigating this concern.

CONCLUSION

In this large cross-sectional cohort of young women with PCOS, insulin resistance was consistently associated with reproducible alterations in CBC-derived leukocyte differential indices, characterized by higher neutrophil percentage, lower lymphocyte percentage, and elevated NLR. These findings support the utility of simple hematological markers as indicators of metabolic–inflammatory interactions in PCOS and provide a foundation for future longitudinal and interventional research.

DATA AND CODE AVAILABILITY

The datasets generated and analyzed during the current study are not publicly available due to ethical and data protection restrictions but are available from the corresponding author on reasonable request. The analysis code used to generate the results reported in this article is publicly available at GitHub: `https://github.com/npiorkowska-science/pcos-cbc-insulin-resistance`

SUPPLEMENTARY MATERIALS

1. Supplementary Table S1. Baseline characteristics of the study population and data availability

Blood Test	Total	Nonmissing	Missing	Missing n %	Mean	Standard deviation	Median	IQR	Min	Max
age	1315	1315	0	0	20.90	1.95	21	3	16	25
CRP	1315	19	1296	98.55	4.72	13.06	0.30	3.55	0.10	58
EOS %	1315	918	397	30.19	2.92	1.82	2.50	1.90	0	15.90
HOMA-IR	1315	1062	253	19.23	1.89	1.46	1.51	1.16	0.15	20.90
IG %	1315	918	397	30.19	0.24	0.14	0.20	0.10	0	1
log(CRP)	1315	19	1296	98.55	0.94	1.01	0.26	1.31	0.09	4.07
log(HOMA-IR)	1315	1062	253	19.24	0.99	0.36	0.92	0.44	0.14	3.09
LYMPH %	1315	918	397	30.19	40.95	7.90	41.25	10.70	11.20	66.20
MONO %	1315	918	397	30.19	8.72	1.85	8.60	2.50	4.40	16.40
MPV	1315	46	1269	96.50	10.49	0.85	10.40	1.22	8.80	12.90
NEUT %	1315	918	397	30.19	46.50	8.24	46.35	10.97	22.80	79.20
NLR	1315	918	397	30.19	1.24	0.58	1.11	0.57	0.37	6.31
P-LCR	1315	46	1269	96.50	28.94	7.045	28.55	10.62	14.50	48.60
PCT	1315	46	1269	96.50	0.29	0.06	0.28	0.08	0.19	0.45
PDW	1315	46	1269	96.50	12.18	1.90	12	2.60	8.70	19.10
PLT	1315	46	1269	96.50	276.52	61.96	263.50	88.25	169	432
RDW	1315	46	1269	96.50	13.01	1.28	12.55	1.37	10.60	17.60
RDW-SD	1315	46	1269	96.50	41.03	2.90	40.45	3.85	36.10	52.10
WBC	1315	46	1269	96.50	6.77	1.93	6.39	2.18	3.77	13.49
GLUCOSE 0'	1315	1174	141	0.89	84.34	6.07	83.90	7.77	51.90	108
INSULIN 0'	1315	1069	246	0.81	9.02	6.67	7.30	5.41	0.20	98.20

2. Supplementary Table S2. Secondary CBC analyses and missingness.

y	x	n	r	p	q
NEUT %	log(HOMA-IR)	900	0.2474	5.1133e14	6.1360e14
LYMPH %	log(HOMA-IR)	900	-0.2079	3.0388e10	1.8233e9
NLR	log(HOMA-IR)	900	0.1938	4.5773e9	1.8309e8
NeUT %	HOMA-IR	900	0.1906	8.2787e9	2.4836e8
IG %	log(HOMA-IR)	900	0.1594	1.5360e6	3.1966e6
NLR	HOMA-IR	900	0.1591	1.5983e6	3.1966e6
LYMPH %	HOMA-IR	900	-0.1520	4.6651e6	7.9974e6
IG %	HOMA-IR	900	0.1253	2.0000e4	2.0000e4
MONO %	log(HOMA-IR)	900	-0.1001	2.6000e3	3.5000e3
MONO %	HOMA-IR	900	-0.0985	3.1000e3	3.7000e3
EOS %	log(HOMA-IR)	900	-0.0931	5.2000e3	5.6000e3
EOS %	HOMA-IR	900	-0.0817	1.4100e2	1.4100e2

3. Supplementary Table S3. Missingness and QC.

Variable	Total n	Non-missing n	Missing n	Missing %
CRP	1315	19	1296	98.5551
log(CRP)	1315	19	1296	98.5551
MPV	1315	46	1269	96.5019
P-LCR	1315	46	1269	96.5019
PCT	1315	46	1269	96.5019
PDW	1315	46	1269	96.5019
PLT	1315	46	1269	96.5019
RDW	1315	46	1269	96.5019
RDW-SD	1315	46	1269	96.5019
WBC	1315	46	1269	96.5019
EOS %	1315	918	397	30.1901
IG %	1315	918	397	30.1901
LYMPH %	1315	918	397	30.1901
MONO %	1315	918	397	30.1901
NEUT %	1315	918	397	30.1901
NLR	1315	918	397	30.1901
HOMA-IR	1315	1062	253	19.2395
log(HOMA-IR)	1315	1062	253	19.2395
Age	1315	1315	0	0

Figures

Figure 1. Association between insulin resistance and neutrophil-to-lymphocyte ratio (NLR)

Figure 2. Forest plot of multivariable regression coefficients for primary leukocyte outcomes

References

[1] Kathleen M. Hoeger, Anuja Dokras, and Terhi Piltonen. Update on pcos: Consequences, challenges, and guiding treatment. *The Journal of Clinical Endocrinology Metabolism*, 106(3):e1071–e1083, 2020.

[2] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (pcos). *Human Reproduction*, 19:41–47, 2004.

[3] J.P. Christ and M.I. Cedars. Current guidelines for diagnosing pcos. *Diagnostics*, 13:1113, 2023.

[4] S. Palomba, M.A. de Wilde, A. Falbo, M.P.H. Koster, G.B. La Sala, and B.C.J.M. Fauser. Pregnancy complications in women with polycystic ovary syndrome. *Human Reproduction Update*, 21:575–592, 2015.

[5] M. Harada. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. *Reproductive Medicine and Biology*, 21:e12487, 2022.

[6] X. Chen, Y. Wan, and L. Xie. Insulin resistance in pcos: Pathophysiological mechanisms of menstrual dysfunction and evidence-based treatment strategies. *Biology of Reproduction*, page ioaf197, 2025.

[7] E. Rudnicka, K. Suchta, M. Grymowicz, A. Calik-Ksepka, K. Smolarczyk, A.M. Duszewska, R. Smolarczyk, and B. Meczekalski. Chronic low grade inflammation in pathogenesis of pcos. *International Journal of Molecular Sciences*, 22:3789, 2021.

[8] N. Helvaci and B.O. Yildiz. Polycystic ovary syndrome as a metabolic disease. *Nature Reviews Endocrinology*, 21:230–244, 2025.

[9] Celia Bañuls, Susana Rovira-Llopis, Aranzazu Martinez de Marañon, Silvia Veses, Ana Jover, Marcelino Gomez, Milagros Rocha, Antonio Hernandez-Mijares, and Victor M. Victor. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte–endothelium interactions in pcos. *Metabolism: Clinical and Experimental*, 71:153–162, 2017.

[10] L. Li, J. Yu, and Z. Zhou. Association between neutrophil-to-lymphocyte ratio and polycystic ovary syndrome: A prisma-compliant systematic review and meta-analysis. *Medicine (Baltimore)*, 101(38):e30579, 2022.

[11] H.D. Ozkan, M. Ayas Ozkan, R. Dayanan, et al. Inflammatory status and clinical phenotypes of pcos: The role of nlr, sii, siri, and aisi. *BMC Women's Health*, 25:463, 2025.